Mid-May, 2025, 24 of the 70 GVAS were tagged "safer" for dividends as they showed positive one-year returns and ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amphastar ...

Online vehicle auction company Copart (NASDAQ:CPRT) missed Wall Street’s revenue expectations in Q1 CY2025, but sales rose ...

Merck & Co. is undervalued with strong oncology growth, key R&D investments, and shareholder returns. Click here to read an ...

Myasthenia gravis is an autoimmune disorder in which antibodies disrupt the communication between nerves and muscles, ...

Genmab A/S announced today that it will present new research from its comprehensive development program evaluating its late-stage portfolio at the 2025 American Society of Clinical Oncology (ASCO) ...

The FDA has approved Johnson & Johnson's anti-FcRn antibody, nipocalimab, for the treatment of generalized myasthenia gravis. The drug will be sold under the brand name IMAAVY. This approval ...